SCHEMBL23494672

SCHEMBL23494672

CC(C)[C@H]1CC[C@@H](NC(=O)c2cc(NC(=O)[C@H]3CC[C@@H](C(C)(C)C)CC3)cc(NC(=O)[C@H]3CC[C@@H](C(C)(C)C)CC3)c2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.49
ROCK2 O75116 4/20 0.47
ROCK1 Q13464 4/20 0.47
HSD17B10 Q99714 1/20 0.42
RXRA P19793 1/20 0.42
RXRB P28702 1/20 0.42
RXRG P48443 1/20 0.42
ACKR3 P25106 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
PKN2 Q16513 3/20 0.38
RPS6KA5 O75582 2/20 0.38
LRRK2 Q5S007 2/20 0.38
HTT P42858 2/20 0.38
TP53 P04637 2/20 0.38
CYP3A4 P08684 2/20 0.38
CHUK O15111 1/20 0.38
PRKD3 O94806 1/20 0.38
CDK1 P06493 1/20 0.38
CDK2 P24941 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23494670 1.00 GLA (0.49) GLAROCK2ROCK1HSD17B10RXRA
SCHEMBL23494739 1.00 GLA (0.49) GLAROCK2ROCK1HSD17B10RXRA
SCHEMBL23494674 1.00 GLA (0.49) GLAROCK2ROCK1HSD17B10RXRA
SCHEMBL23494738 1.00 GLA (0.49) GLAROCK2ROCK1HSD17B10RXRA
SCHEMBL23494707 1.00 GLA (0.49) GLAROCK2ROCK1HSD17B10RXRA
SCHEMBL23494744 0.92 ROCK2 (0.54) ROCK2ROCK1HSD17B10PKN2RPS6KA5
SCHEMBL23494665 0.92 GLA (0.57) GLAHSD17B10RXRARXRBRXRG
SCHEMBL23494666 0.92 GLA (0.57) GLAHSD17B10RXRARXRBRXRG
SCHEMBL23494746 0.92 ROCK2 (0.54) ROCK2ROCK1HSD17B10PKN2RPS6KA5
SCHEMBL23494701 0.92 GLA (0.57) GLAHSD17B10RXRARXRBRXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4317128-B1 TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME MILLIKEN & CO (US) 2025-07-23 EP claimed
US-12358864-B2 Trisamide compounds and compositions comprising the same MILLIKEN & COMPANY (US) 2025-07-15 US claimed
CN-117756661-A Triamide compound and composition comprising same 美利肯公司 2024-03-26 CN claimed
EP-4317128-A2 TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME Milliken & Company (US) 2024-02-07 EP claimed
US-20230331660-A1 TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME MILLIKEN & COMPANY 2023-10-19 US claimed
EP-4317128-B1 TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME MILLIKEN & CO (US) 2025-07-23 EP disclosed
US-12358864-B2 Trisamide compounds and compositions comprising the same MILLIKEN & COMPANY (US) 2025-07-15 US disclosed
CN-117756661-A Triamide compound and composition comprising same 美利肯公司 2024-03-26 CN disclosed
EP-4317128-A2 TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME Milliken & Company (US) 2024-02-07 EP disclosed
EP-4073029-B1 TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME MILLIKEN & CO (US) 2024-01-31 EP disclosed
CN-115066413-B Triamide compound and composition comprising same 美利肯公司 2024-01-09 CN disclosed
US-20230331660-A1 TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME MILLIKEN & COMPANY 2023-10-19 US disclosed
US-11724983-B2 Trisamide compounds and compositions comprising the same MILLIKEN & COMPANY (US) 2023-08-15 US disclosed
EP-4073029-A1 TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME Milliken & Company (US) 2022-10-19 EP disclosed
CN-115066413-A Triamide compounds and compositions comprising the same 美利肯公司 2022-09-16 CN disclosed
US-20210179540-A1 TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME MILLIKEN & COMPANY 2021-06-17 US disclosed
WO-2021119633-A1 TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME MILLIKEN & COMPANY (US) 2021-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11724983-B2 Trisamide compounds and compositions comprising the same PTAR1, TIPRL, TCOF1 GLA 612/4885ROCK2 1959/4885ROCK1 1818/4885
US-20230331660-A1 TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME PTAR1, TIPRL, TCOF1 GLA 612/4885ROCK2 1959/4885ROCK1 1818/4885
US-20210179540-A1 TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME PTAR1, TIPRL, TCOF1 GLA 612/4885ROCK2 1959/4885ROCK1 1818/4885
US-12358864-B2 Trisamide compounds and compositions comprising the same PTAR1, TIPRL, TCOF1 GLA 612/4885ROCK2 1959/4885ROCK1 1818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.